2 results
2085: MyResearchHome@Duke—launch and adoption of a portal for the research community
- Rebecca Namenek Brouwer, Rebbecca Moen, Iain Sanderson, Ebony Boulware, Johanna O’Dell, Kellie Morris Browning
-
- Journal:
- Journal of Clinical and Translational Science / Volume 1 / Issue S1 / September 2017
- Published online by Cambridge University Press:
- 10 May 2018, p. 11
-
- Article
-
- You have access Access
- Open access
- Export citation
-
OBJECTIVES/SPECIFIC AIMS: Describe (1) the features of the first release of Duke’s myRESEARCHhome portal for researchers, and 2) the methods and results of adoption strategies METHODS/STUDY POPULATION: Through methods described previously (cite ACTS poster, 2016), the myRESEARCHhome portal team conducted a needs assessment to determine priorities for inclusion in the tool. Based on results of that assessment, the “minimal viable product” launched in June 2016 included the following features, organized into 9 distinct widgets: Access to all web-based research applications; ability to find and request research services; at-a-glance view of financial, protocol, and salary distribution information; access to financial and personnel reports; access to status of agreements and patents; access to CTSA-supported navigation services; visibility into required training and expiration dates; listing of announcements relevant to researchers; customized links area; ability to customize portal. The portal was developed using Ruby on Rails™, with a REACT grid framework. The development team, internal to Duke University, followed industry-standard best practices for development. After the initial release, the team employed several strategies to ensure awareness and adoption. Although written communications were an important factor for awareness, the presentations and hands-on studios proved most important. RESULTS/ANTICIPATED RESULTS: Use of the portal was directly related to in-person outreach efforts. There were small spikes after written communications, but strategies such as presentations, hands-on demonstrations, training sessions, and faculty meetings garnered the steadiest adoption rates. As of early January, 2017, almost 3000 users have interacted with the portal, with numbers rising steadily. There are an estimated 10,000+ faculty, staff, and trainees engaged in research at Duke. DISCUSSION/SIGNIFICANCE OF IMPACT: To maintain high adoption rates with the research community, engagement strategies must be ongoing. In addition to frequent in-person demonstrations, updates via written communications, and attendance at events, the portal team will employ a key adopt strategy—engaging the researchers in ongoing needs assessments. By maintaining the portal’s relevance to the needs of the research community, the tool can better improve the efficiency of research at a large academic medical center.
17 - What is the neuropathological basis of dementia associated with Lewy bodies?
- from Part two - Pathological issues
- Edited by Robert Perry, Department of Neuropathology, Newcastle General Hospital, Ian McKeith, University of Newcastle upon Tyne, Elaine Perry, MRC Neurochemical Pathology Unit, Newcastle General Hospital
- Foreword by Jeffrey L. Cummings
-
- Book:
- Dementia with Lewy Bodies
- Published online:
- 06 July 2010
- Print publication:
- 28 November 1996, pp 212-223
-
- Chapter
- Export citation
-
Summary
Summary
Two alternative hypotheses – that there is either a unitary or a multiple neuropathological basis for dementia in diseases associated with Lewy bodies – are considered in relation to Parkinson's disease (PD) and Lewy body dementia (LBD including senile dementia of Lewy body type, SDLT). Densities of limbic (cingulate) cortical Lewy bodies, neocortical Lewy bodies, neocortical plaques, neocortical tangles, Braak staging, and Apo E frequency have been quantified in PD (demented and nondemented), SDLT, and Alzheimer's disease (AD with presenile and senile onset). Of these parameters the mean density of cingulate Lewy bodies is significantly greater in SDLT compared with all PD cases. There is no obvious correlation between Lewy body density and cognitive impairment assessed using a simple test of mental ability, and other measures of mental function in LBD may need to be considered. Since there is no absolute density of limbic Lewy bodies that clearly differentiates SDLT or demented PD cases from all nondemented PD cases, neuropathological criteria may need to incorporate severity of Alzheimer-type pathology as an additional optional factor. Mean neocortical plaque density is significantly lower in SDLT compared with AD cases but it is also significantly higher than in demented and nondemented PD cases, and higher than densities in normals. Even so, neocortical plaque density does not itself differentiate all SDLT cases from the normal. It is likely that the biological basis for dementia or psychoses in LBD, a cardinal feature of which is fluctuating symptomatology, is in part a functional or neurochemical abnormality.